Eventide Asset Management, LLC Celldex Therapeutics, Inc. Transaction History
Eventide Asset Management, LLC
- $5.22 Billion
- Q4 2024
A detailed history of Eventide Asset Management, LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Eventide Asset Management, LLC holds 3,753,260 shares of CLDX stock, worth $85.2 Million. This represents 1.82% of its overall portfolio holdings.
Number of Shares
3,753,260
Previous 3,332,005
12.64%
Holding current value
$85.2 Million
Previous $113 Million
16.21%
% of portfolio
1.82%
Previous 1.99%
Shares
17 transactions
Others Institutions Holding CLDX
# of Institutions
206Shares Held
70.2MCall Options Held
1.46MPut Options Held
868K-
Wellington Management Group LLP Boston, MA8.98MShares$204 Million0.04% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.06MShares$115 Million8.11% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$106 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.88MShares$88.1 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.56MShares$80.7 Million0.01% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.06B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...